Back to search results

Registry of Deep Brain Stimulation with the Vercise System for Parkinson's Disease

This registry is observing how well Boston Scientific's Vercise Deep Brain Stimulation (DBS) system works for people with Parkinson's disease. DBS is a surgical treatment that involves implanting a device to send electrical impulses to specific areas of the brain. The study will look at how the Vercise DBS system, including its Image Guided Programming (IGP) and DBS Illumina 3D features, affects your quality of life over up to three years. You might be able to join if you are at least 18 years old and meet the Vercise System's usage criteria. The study aims to understand the real-world results of this treatment.

Study design
This is an observational study, meaning researchers will collect information about people already using the Vercise DBS system. It plans to include about 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be assessed for up to 3 years after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02071134

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Recruiting
Not specifiedAges 18+Observational
Boston Scientific Corporation
~1,500 participants
Updated 2026-09-16 on ClinicalTrials.gov
What's tested:Deep Brain Stimulation (DBS)

At a glance

Recruiting sites
34 of 86 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Improvement in patient's quality of life (QoL) during the study as compared with baseline
Measured over up to 3 years

Conditions

Parkinson's Disease

Explore related trials

Parkinson Disease

NCT02071134

Where you'd take part

This study runs at 86 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • A.o. LKH Univ.-Kliniken Innsbruck

    Innsbruck, Austriastudy coordinator listed

    Recruiting

  • Bahcesehir University Hospital Medical Park Goztepe

    Istanbul, Turkey (Türkiye)study coordinator listed

    Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

  • Charing Cross Hospital

    London, United Kingdomstudy coordinator listed

    Recruiting

  • Evangelisches Krankenhaus Oldenburg

    Oldenburg, Germanystudy coordinator listed

    Recruiting

  • Evergreen Health

    Kirkland, Washingtonstudy coordinator listed

    Recruiting

  • Fundacion Ineco-Research Facility

    Buenos Aires, Argentinastudy coordinator listed

    Recruiting

  • Hospital General De Asturias

    Oviedo, Spainstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Natalie Bloom Lyons · STUDY_DIRECTOR · Boston Scientific Neuromodulation Corporation

Who to contact

Heleen Scholtes
[email protected]
855-213-9890
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meets criteria established in locally applicable Vercise System Direction for Use
At least 18 years old

Exclusion

Meets any contraindication in the Vercise System locally applicable Directions for Use

What this trial measures

  • Improvement in patient's quality of life (QoL) during the study as compared with baselineup to 3 years

    Change in quality of life assessments during the study as compared with baseline